Relmada Therapeutics (RLMD) said it is prioritizing manufacturing activities for NDV-01, its sustained-release intravesical gemcitabine/docetaxel for non-muscle invasive bladder cancer. The company is targeting an IND filing by end-2026 as it advances toward next regulatory milestones. This is a forward-looking operational update with limited immediate financial impact.
Relmada Therapeutics (RLMD) said it is prioritizing manufacturing activities for NDV-01, its sustained-release intravesical gemcitabine/docetaxel for non-muscle invasive bladder cancer. The company is targeting an IND filing by end-2026 as it advances toward next regulatory milestones. This is a forward-looking operational update with limited immediate financial impact.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
